| 主权项 |
1. A method of treating a cancer in a patient, comprising administering to the patient suffering from a cancer a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: in which groups R1-R5 and m are as follows R1: lower alkylene-OH, lower alkylene-N(R0)(R6), lower alkylene-CO2R0, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, -(lower alkylene substituted with —OR0)-aryl or lower alkylene-heterocyclic group, wherein the lower alkylene, cycloalkyl, cycloalkenyl, aryl and heterocyclic group in R1 may each be substituted, R0: the same as or different from each other, each representing —H or lower alkyl, R6: R0, —C(O)—R0, —CO2-lower alkyl or —S(O)2-lower alkyl, R2: lower alkyl, lower alkylene-OR0, lower alkylene-aryl, lower alkylene-heterocyclic group, lower alkylene-N(R0)CO-aryl, lower alkylene-O-lower alkylene-aryl, —CO2R0, —C(O)N(R)2, —C(O)N(R0)-aryl,) —C(O)N(R0)-lower alkylene-aryl, or aryl, wherein the aryl and heterocyclic group in R2 may each be substituted, R3: —H or lower alkyl, or R2 and R3 may be combined to form C2-6 alkylene, R4: —N(R7)(R8), —N(R0)—OH, —N(R10)—OR7, —N(R0)—N(R0)(R7), —N(R0)—S(O)2-aryl, or —N(R0)—S(O)2—R7, wherein the aryl in R4 may be substituted, R7: lower alkyl, halogeno-lower alkyl, lower alkylene-CN, lower alkylene-OR0, lower alkylene-CO2R0, lower alkylene-C(O)N(R0)2, lower alkylene-C(O)N(R0)N(R0)2, lower alkylene-C(═NH)NH2, lower alkylene-C(═NOH)NH2, heteroaryl, lower alkylene-X-aryl, or lower alkylene-X-heterocyclic group, wherein the lower alkylene, aryl, heteroaryl, and heterocyclic group in R7 may each be substituted, X: single bond, —O—, —C(O)—, —N(R0), —S(Op—, or *—C(O)N(R0)—, wherein * in X represents a bond to lower alkylene, m: an integer of 0 to 3, p: an integer of 0 to 2, R8: —H or lower alkyl, or R7 and R8 may be combined to form lower alkylene-N(R9)-lower alkylene, lower alkylene-CH(R9)-lower alkylene, lower alkylene-arylene-lower alkylene, or lower alkylene-arylene-C(O)—, R9: aryl and heteroaryl which may each be substituted, R10: —H, lower alkyl, or —C(O)R0, R5: lower alkyl, halogeno-lower alkyl, halogen, nitro, —OR0, —O-halogeno-lower alkyl, —N(R0)2, —O-lower alkylene-CO2R0, or —O-lower alkylene-aryl, wherein the aryl in R5 may be substituted,
provided that, when R4 is —N(R7)(R8),(1) a compound wherein R1 is unsubstituted cyclopentyl and R2 is unsubstituted 2-thienyl;(2) a compound wherein R1 is unsubstituted cyclohexyl and R2 is 4-methoxyphenyl;(3) a compound wherein R1 is 4-methoxyphenyl and R2 is 4-methoxyphenyl; and(4) a compound wherein R1 is (morpholin-4-yl)ethyl and R2 is 4-ethoxyphenyl are excluded, and further provided that, 2,3-bis(4-chlorophenyl)-N-(2-methoxyethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, 3-(4-chlorobenzyl)-2-(4-chlorophenyl)-N-(2-methoxyethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, 3-[3,5-bis(trifluoromethyl)phenyl]-2-cyclopropyl-N-(2-furylmethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, 3-[3,5-bis(trifluoromethyl)phenyl]-2-cyclopropyl-N-(2-methoxyethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, ethyl 3-{3-[3,5-bis(trifluoromethyl)phenyl]-4-{[2-(4-methoxyphenyl)ethyl]carbamoyl}-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl}propanoate, N-benzyl-3-[3,5-bis(trifluoromethyl)phenyl]-1-oxo-2-(tetrahydrofuran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, 3-[3,5-bis(trifluoromethyl)phenyl]-N-(2-methoxyethyl)-2-(2-morpholin-4-ylethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, 3-[3,5-bis(trifluoromethyl)phenyl]-2-(2-furylmethyl)-N-(2-methoxyethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, 3-[3,5-bis(trifluoromethyl)phenyl]-N-(2-furylmethyl)-2-(2-morpholin-4-ylethyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide, and (4-chlorophenyl)[3-(4-chlorophenyl)-4-[(2-methoxyethyl)carbamoyl]-1-oxo-3-,4-dihydroisoquinolin-2(1H)-yl]acetic acid are excluded. |
